$0.1805
0.00170.95%
At close: Nov 13, 4:00 PM EST
$0.1788
-0.0017-0.94%
After Hours: Nov 13, 7:05 PM EST
Vistagen Therapeutics Inc
VTGNNASDAQ
Vistagen Therapeutics fell 95.3% from $3.80 to $0.18, behind the S&P 500's +12.3%. Its worst day was Dec 17 (−80.3%), and its low came Nov 6 at $0.16.
Nov 14, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Vistagen Therapeutics closed at its highest level of the year, 28.9% above where the year started.
+7.9% · S&P 500 +0.5%
Vistagen Therapeutics shares fell 80.3%, while the S&P 500 fell 1.1%.
Story events cover the past 12 months · Times ET
−80.3%, the year's worst day · S&P 500 −1.1%
EPS of $-0.45 missed the $-0.39 estimate on $303,000.00 revenue (est. $256,520.00).
−7.2% · S&P 500 +0.1%
EPS of $-0.37 missed the $-0.30 estimate on $465,000.00 revenue (est. $320,000.00).
+20.4% · S&P 500 −0.6%
Vistagen Therapeutics shares fell 70.3%, while the S&P 500 rose 0.8%.
−70.3% · S&P 500 +0.8%
EPS of $-0.30 beat the $-0.35 estimate on $1.5M revenue (est. $166,670.00).
+0.5% · S&P 500 −0.2%
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.
+46.5%, the year's best day, on 575M shares, the year's heaviest volume · S&P 500 −0.7%
Vistagen Therapeutics closed at its lowest level of the year, 95.7% below where the year started.
−0.8% · S&P 500 +0.3%
Where it ended: a close of $0.18 on Nov 13, 2026. Up next: Q3 2027 earnings on Feb 11, 2027 (EPS est. $-0.36, revenue est. $250,000.00).
Nothing in the past 12 months.
All VTGN dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VTGN and SPY from Benzinga historical bars. Not investment advice.
